Summary
Patients who receive a type of transplant called a haploidentical haematopoietic stem cell transplant (haplo-HSCT), which is not an ideal tissue match for the patient, are at a high risk of developing a viral infection. This is because the immune cells that can fight viruses (caleld T-cells) are removed from the transplant before it is given.
In this trial, researchers will rest a new preventative T-cell therapy for four common viruses in people who have received a haplo-HSCT. The therapy will be grown from the blood of the transplant donor and given to patients after their transplant.
One aim of this trial is to see if this T-cell therapy is safe for transplant patients. In addition, we would like to see if the T-cells that we grow in the laboratory from the transplant donors can help to restore the recipients' immune systems. This may help prevent infectious complications from developing.